Mia D SÃ¸rensen

List of Publications by Year
in descending order

34 papers	724 citations	706676 14 h-index	651938 25 g-index
34 all docs	34 docs citations	34 times ranked	1533 citing authors

#	Article	IF	Citations
1	Tumour‑associated CD204⁺ microglia/macrophages accumulate in perivascular and perinecrotic niches and correlate with an interleukin‑6‑enriched inflammatory profile in glioblastoma. Neuropathology and Applied Neurobiology, 2022, 48, .	1.8	12
2	Stage-dependent expression of fibrogenic markers in alcohol-related liver disease. Pathology Research and Practice, 2022, 231, 153798.	1.0	9
3	The Epigenetic Regulator Jumonji Domain-Containing Protein 6 (JMJD6) Is Highly Expressed but Not Prognostic in IDH-Wildtype Glioblastoma Patients. Journal of Neuropathology and Experimental Neurology, 2022, 81, 54-60.	0.9	1
4	Albumin-corrected Zn and available free Zn-binding capacity as indicators of Zn status – potential for clinical implementation. Scandinavian Journal of Clinical and Laboratory Investigation, 2022, 82, 261-266.	0.6	3
5	Targeted next‑generation sequencing of adult gliomas for retrospective prognostic evaluation and up‑front diagnostics. Neuropathology and Applied Neurobiology, 2021, 47, 108-126.	1.8	10
6	The presence of TIM‑3 positive cells in WHO grade III and IV astrocytic gliomas correlates with isocitrate dehydrogenase mutation status. Brain Pathology, 2021, 31, e12921.	2.1	5
7	Microglia-Secreted Factors Enhance Dopaminergic Differentiation of Tissue- and iPSC-Derived Human Neural Stem Cells. Stem Cell Reports, 2021, 16, 281-294.	2.3	23
8	Gene expression profiling of morphologic subtypes of pancreatic ductal adenocarcinoma using surgical and EUS-FNB specimens. Pancreatology, 2021, 21, 530-543.	0.5	6
9	Prognostic role of Ki-67 in glioblastomas excluding contribution from non-neoplastic cells. Scientific Reports, 2021, 11, 17918.	1.6	22
10	Expression Profiling of Primary and Recurrent Glioblastomas Reveals a Reduced Level of Pentraxin 3 in Recurrent Glioblastomas. Journal of Neuropathology and Experimental Neurology, 2020, 79, 975-985.	0.9	13
11	Sodium fluorescein shows high surgeon-reported usability in glioblastoma surgery. Journal of the Royal College of Surgeons of Edinburgh, 2020, 18, 344-348.	0.8	9
12	Alternative lengthening of telomeres is the major telomere maintenance mechanism in astrocytoma with isocitrate dehydrogenase 1 mutation. Journal of Neuro-Oncology, 2020, 147, 1-14.	1.4	18
13	Prediction of liver fibrosis severity in alcoholic liver disease by human microfibrillar‑associated protein 4. Liver International, 2020, 40, 1701-1712.	1.9	19
14	Spatial and phenotypic characterization of pancreatic cancer-associated fibroblasts after neoadjuvant treatment. Histology and Histopathology, 2020, 35, 811-825.	0.5	6
15	Overexpression of TIMP-1 and Sensitivity to Topoisomerase Inhibitors in Glioblastoma Cell Lines. Pathology and Oncology Research, 2019, 25, 59-69.	0.9	3
16	High expression of cystine‑glutamate antiporter xCT (SLC7A11) is an independent biomarker for epileptic seizures at diagnosis in glioma. Journal of Neuro-Oncology, 2018, 138, 49-53.	1.4	40
17	Prognostic value of O‑6‑methylguanine‑DNA methyltransferase (MGMT) protein expression in glioblastoma excluding nontumour cells from the analysis. Neuropathology and Applied Neurobiology, 2018, 44, 172-184.	1.8	34
18	Tumour‑associated microglia/macrophages predict poor prognosis in high‑grade gliomas and correlate with an aggressive tumour subtype. Neuropathology and Applied Neurobiology, 2018, 44, 185-206.	1.8	178

#	Article	IF	Citations
19	P01.114 Expression and prognostic value of the immune checkpoint molecule galectin-9 in glioblastomas. Neuro-Oncology, 2018, 20, iii257-iii258.	0.6	0
20	P01.083 Expression and prognostic value of the immune checkpoint molecule galectin-9 in glioblastomas. Neuro-Oncology, 2018, 20, iii249-iii249.	0.6	0
21	Aberrant neuronal differentiation is common in glioma but is associated neither with epileptic seizures nor with better survival. Scientific Reports, 2018, 8, 14965.	1.6	6
22	Co-expression of TIMP-1 and its cell surface binding partner CD63 in glioblastomas. BMC Cancer, 2018, 18, 270.	1.1	29
23	SuperQuant-assisted comparative proteome analysis of glioblastoma subpopulations allows for identification of potential novel therapeutic targets and cell markers. Oncotarget, 2018, 9, 9400-9414.	0.8	8
24	Expression and prognostic value of JAM-A in gliomas. Journal of Neuro-Oncology, 2017, 135, 107-117.	1.4	15
25	Expression and prognostic impact of matrix metalloproteinase-2 (MMP-2) in astrocytomas. PLoS ONE, 2017, 12, e0172234.	1.1	60
26	APNG as a prognostic marker in patients with glioblastoma. PLoS ONE, 2017, 12, e0178693.	1.1	11
27	Transferrin receptor-1 and ferritin heavy and light chains in astrocytic brain tumors: Expression and prognostic value. PLoS ONE, 2017, 12, e0182954.	1.1	61
28	A 4-miRNA signature to predict survival in glioblastomas. PLoS ONE, 2017, 12, e0188090.	1.1	21
29	Expression and Prognostic Value of Oct-4 in Astrocytic Brain Tumors. PLoS ONE, 2016, 11, e0169129.	1.1	14
30	Shift of microRNA profile upon orthotopic xenografting of glioblastoma spheroid cultures. Journal of Neuro-Oncology, 2016, 128, 395-404.	1.4	6
31	Migrating glioma cells express stem cell markers and give rise to new tumors upon xenografting. Journal of Neuro-Oncology, 2016, 130, 53-62.	1.4	29
32	TMIC-18 TUMOR-ASSOCIATED MICROGLIA/MACROPHAGES ARE ASSOCIATED WITH POOR PROGNOSIS IN HIGH-GRADE GLIOMAS AND CONTRIBUTE TO THE GLIOBLASTOMA STEM CELL-LIKE NICHES. Neuro-Oncology, 2015, 17, v218.6-v218.	0.6	0
33	Chemoresistance and Chemotherapy Targeting Stem-Like Cells in Malignant Glioma. Advances in Experimental Medicine and Biology, 2015, 853, 111-138.	0.8	43
34	Novel approaches for quantifying protein biomarkers in gliomas: benefits and pitfalls. CNS Oncology, 2014, 3, 287-298.	1.2	10